We have performed an analysis of ras, c-myc, c-myb, c-erbBl and c-erbB2 onocogenes in 100 surgical samples of human breast carcinomas. No point mutations have been detected at the 12th codon of cHa-ras and c-Ki-ras in 40 and 65 breast cancer DNAs, respectively. One out of 65 samples showed a 50-fold amplification of c-Ha-ras that, however, was not overexpressed. Alterations in the structure of c-myc, c-myb c-erbBl and c-erbB2 oncogenes were sporadically observed. In 20 tumour samples, the study of expression of a series of oncogenes revealed that c-Ha-ras was the predominantly transcribed gene among the ras gene family whereas c-fos appeared the most constantly and significantly expressed nuclear oncogene.
Genetic changes which contribute to the onset and progression of cancer are still largely obscure in spite of the fact that the activation of certain cellular proto-oncogenes has frequently been implicated in most types of human tumours. In particular, mutated alleles of ras family genes have been found in about 15% of the most common forms of human cancers (Pulciani et al., 1982) and several proto-oncogenes have been found to be amplified in a variety of tumour cell lines and primary tumours (Alitalo et al., 1983; Escot et al., 1986; Kozbor & Croce, 1984; Little et al., 1983; Yokota et al., 1986) . In breast cancer, the only report of a DNA transforming activity was provided by Kraus et al. (1984) who showed the activation of the c-Ha-ras oncogene in a carcinosarcoma cell line. Amplifications and/or alterations of c-myc and c-myb were reported in both cell lines and fresh samples of breast carcinomas Kozbor & Croce, 1984; Yokota et al., 1986) . A cellular gene related to v-erbB, c-erbB2/neu, was also found amplified in breast cancer and the amplification was suggested to be of prognostic value (Slamon et al., 1987) . Finally. Theillet et al. (1986) detected a loss of c-Ha-ras alleles in a significant number of breast cancer DNAs and suggested a relation to aggressively growing tumours.
In this report we present the results of the analysis of the genomic organisation of several oncogenes in 100 cases of human breast carcinomas and of a study of oncogene expression in 20 of them.
Patients and methods

Case material
Tumour specimens from 83 primary breast carcinomas and 17 lymph node metastases were collected from an unselected series of 100 patients observed at our Institute. The tumours were classified following the WHO Histological Typing of Breast Tumours (1981) (Southern, 1975) .
The filters were hybridized with 32P labelled probes for 18 h and washed extensively under stringent conditions. After being dried, the filters were exposed at -70°C with Trimax 3M XR films with intensifying screens for varying periods of time.
RNA isolation, poly(A)+ selection, Northern and slot blot analysis Cesium chloride gradient centrifugation was used to isolate the RNA from solubilized tissue samples and from PBL according to previously described procedure (Raymond & Shore, 1979) . Poly(A +) RNA was obtained by passing the total RNA extracted on Hybond TM-mAP paper (Amersham). Poly(A +) RNA was electrophoresed in 1% agarose containing formaldehyde as previously described (Southern, 1975) . Total RNA was used for slot blot analysis as was previously described by Slamon et al. (1984) . The level of hypoxanthine phosphoribosyltransferase expression was used to normalize the relative amount of RNA in the different tissue samples. Autoradiographic scans were performed with a laser densitometric scanner (LKB).
Probes
The human c-Ha-ras (pbcNl) Bam HI 6.6kb fragment and c-Ki-ras (pESl9) Sau 3A fragment were given by Dr M. Barbacid (Pulciani et al., 1982; Santos et al., 1984) . The pKyl probe detecting RFLP at c-Ha-ras 12th codon, was provided by Dr M. containing the entire c-myc 3rd exon and part of the 2nd exon (Marcu et al., 1983 ) and c-myb representing a 1.2kb PstI DNA fragment from K562 cell line (Pelicci et al., 1984) were both provided by Dr C. Croce. c-erbBl/EGF-R gene probe EcoRI 770 bp fragment was provided by Dr M. Waterfield (Libermann et al., 1985) . c-erbB2/neu gene was detected with the SacI-EcoRI 1.9kb fragment from v-erbB provided by Dr B. Vennstr6m (Damm et al., 1987) . The cfos probe was provided by Dr I. Verma and represented an EcoRI 9.0kb DNA fragment of the human pc-fos plasmid (Miller et al., 1984) . The c-mos (LE392) plasmid was a 2.75 kb EcoRI fragment given by Dr G.F. Vande Woude (Oskarsson et al., 1980) .
Results
Analysis of the structure of the ras genes Mutation of the 12th codon of c-Ha-ras and c-Ki-ras The DNAs of 40 human carcinomas were digested with an excess of Hpa II and MspI restriction enzymes and analysed in Southern blot using the 411 bp MspI DNA fragment (pKyl) derived from the first exon of the c-Ha-ras oncogene ( Figure  IA ) (Kraus et al., 1984) . None of them showed evidence of an activating mutation at the 12th codon of the c-Ha-ras oncogene. As shown in Figure 1B , 4 representative tumour DNAs and a DNA from PBL hybridized as a single 355 bp fragment whereas the mutated c-Ha-ras oncogene from T24 bladder carcinoma cell line yielded a single 411 bp DNA fragment.
Using a similar approach we have analysed 65 tumour samples for c-Ki-ras activation. Using pES19 as probe, a point mutation at the 34th or 35th position of the first exon of c-Ki-ras would generate a recognition site for the enzymes Sacd and Fnu4H I, respectively (Santos et al., 1984) . No base substitutions were observed in any of the samples analysed (data not shown).
Amplification and rearrangement of c-Ha-ras, c-Ki-ras and Nras proto-oncogenes We have analyzed the DNAs of 65 breast carcinomas for structural amplification and/or rearrangement of ras proto-oncogenes. c-Ha-ras was found unaltered in all tumour samples but one that showed a 50-fold amplification of the gene. The amplification was seen only in the tumour DNA and not in the DNA extracted from PBL of the same patient (Figure 2) . None of the 65 samples showed any alterations of c-Ki-ras and N-ras genes.
Loss of c-Ha-ras allele Using a TaqI c-Ha-ras polymorphism (Pierotti et al., 1986 ) the reported loss of a c-Ha-ras allele was evaluated. Southern blot analysis of DNA extracted from 29 primary tumours and matching PBL and from the tumour specimens of 6 patients who were heterozygous for the c-Ha-ras locus, revealed the loss of one allele in 3 cases (8.6%), as shown in Figure 3 . However, 2 DNAs contained a 2-and a 18-fold amplification of the gene, respectively. The latter DNA was analysed at different concentrations as shown in Figure 4 and compared to the DNA of HL-60 and of the PBL of the same patient.
The DNAs of 43 tumour samples had the normal c-myb germ line Hind III fragments of 7.4 and 4.1 kb. Two samples contained an extra 8.3 kb band, which appears to have substituted the normal 4.1 kb fragment ( Figure 5 ).
We analyzed 20 breast carcinoma DNAs for c-erbBI/ EGF-R amplification and/or rearrangement and found that one case contained rearranged bands. The rearrangement was observed with EcoRI that yielded a 4.2kb band in the DNA prepared from the tumour and not in the DNA extracted from PBL of the same patient (Figure 6 panel 1 Using as a probe a fragment of v-erbB oncogene similar to that described by King et al. (1985) that allows the detection of c-erbB2/neu related sequences, we examined the DNA from tumour and PBL of 25 patients. An amplification of c-erbB2/neu gene was observed in 2 cases, one of which is shown in Figure 7 (lane 2).
Oncogene expression
The level of expression of 8 oncogenes was determined in 20 RNAs extracted from primary breast carcinoma specimens (Table I ). The RNA levels were established from slot blot Figure 8 Northern analysis of the expression of c-Ha-ras in human breast carcinoma patients. 5 (Slamon et al., 1984) have used PBL as control material because of the difficulty in obtaining normal breast tissue. The expression of c-fos was scored positive in 75% of the tested samples. Among the ras gene family, c-Ha-ras was significantly transcribed in 65% of the cases whereas c-Kiras and N-ras were positively expressed in 30% and 15% of the samples, respectively, and only one of the 20 samples showed simultaneous expression of the three ras genes. Cmyc, c-myb, c-mos and EGF-R were also found expressed with a frequency ranging from 20 to 30%. As shown in Figure 8 , a Northern blot analysis with c-Haras probe and Poly(A+) mRNAs of 8 cases confirmed the expression of c-Ha-ras of the samples scored positive in the slot blot assay. It should be noted that the mRNA in lane f of Figure 8 derives from the tumour that displayed a 50-fold amplification of c-Ha-ras gene that clearly was not over-expressed.
The analysis of pathological parameters showed no significant correlations between the size of the tumours and the number of positive lymph nodes and the level of transcription of c-Ha-ras and of c-fos (Table I ).
Discussion
The purpose of our work was to analyze the genic structure of the ras oncogenes and of other oncogenes most frequently found altered in fresh human tumours, in order to find possible molecular alterations which could be correlated with breast cancer.
Using an RFLP approach (Kraus et al., 1984; Santos et al., 1984) , we analyzed point mutations affecting the 12th codon of the c-Ha-ras and c-Ki-ras oncogenes in 40 and 65 cases, respectively, and in none of them were base substitutions at these sites identified. Due to lack of appropriate probes, we were unable to analyse point mutations affecting other codons of c-Ha-ras and c-Ki-ras or mutations of N-ras; however, most of the cases were also analyzed in a standard transfection assay and found negative (S. Sukumar and M. Barbacid, personal communication) . This negative observation is in keeping with the fact that, so far, only one report has shown an activation, by point mutation, of the c-Ha-ras oncogene in a breast carcinosarcma cell line whose DNA displayed transforming activity in the NIH-3T3 transfection assay (Kraus et al., 1984) , whereas a large study on more than 100 samples was negative . This suggests that ras oncogene activation must occur very infrequently, if at all, in human breast cancer. Also gene amplification does not seem to play a role since we found a 50-fold c-Ha-ras gene amplification in only one tumour which, moreover, did not demonstrate overexpression of the gene. (Ali et al., 1987) . In 35 breast cancer patients for which matching PBL were available or the tumour tissue displayed heterozygosity, we found that only 8.6% had lost one c-Ha-ras locus. Consequently, it appears that in our sampling the loss of c-Ha-ras alleles is related to stochastic events as was suggested by other investigators studying this phenomenon in human melanomas (Dracopoli et al., 1985) .
As for the expression of ras genes, we found that c-Ha-ras was the most constantly transcribed gene, in agreement with other reports Theillet et al., 1986) but in contrast with the results of Whittaker et al. (1986) who reported on the absence of c-Ha-ras transcripts both in normal and breast carcinoma samples. The discrepancy may be due to differences in the probes used.
We attempted to correlate the expression of ras oncogene with pathological data and observed no significant correlations.
Alterations of c-myc and c-myb have been suggested to occur most frequently in highly aggressive ductal and metastatic breast carcinomas Kozbor & Croce, 1984; Yokota et al., 1986) . Our study detected c-myc amplification in 2 out of 45 cases and c-myb rearrangement in 2 out 43, and did not allow any clinical correlation. The discrepancy between our c-myc data and those reported by Escot et al. (1986) may be due to the difference in histopathological grading and age of the patients under analysis. Escot found c-myc amplification mainly in patients over 50 years whereas our patients averaged 42 years. Recently, it has been shown that the number of metastatic lymph nodes in breast cancer was correlated with the amplification of the c-erbB2/neu gene, which therefore seems to be a prognostic indicator (Slamon et al., 1987) . We found an amplification of the c-erbB2/neu gene in only 2 of our unselected series of 25 breast carcinoma patients. Rearrangement of c-erbBl/ EGF-R gene occurred in only one case. As for the expression of the oncogenes whose product has been localized in the nucleus, only c-fos resulted consistently expressed and this may be due to infiltrating macrophages, which can contribute to c-fos expression in solid breast tumours (Gottlinger et al., 1985) .
In conclusion, our data indicate that none of the presently investigated oncogenes appears to play a key role in the development of breast carcinomas. We stress therefore the need to develop new approaches in order to identify genes involved in the initial events of cellular transformation in this highly frequent human neoplasia.
